Full Name | Acer, Llc |
---|---|
Speciality | Clinic/Center |
Location | 115 Christian Ln, Slidell, Louisiana |
Authorized Official Name and Position | Morris C. Hawkins (CEO) |
Authorized Official Contact | 9856906622 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Acer, Llc 115 Christian Ln Slidell LA 70458-1350 Ph: (985) 690-6622 | Acer, Llc 115 Christian Ln Slidell LA 70458-1350 Ph: (985) 690-6622 |
NPI Number | 1245375203 |
---|---|
Provider Enumeration Date | 02/20/2007 |
Last Update Date | 10/23/2018 |
Medicare PECOS PAC ID | 1153505235 |
---|---|
Medicare Enrollment ID | O20110414000334 |
News Archive
Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.
Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).
Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability.
A new voter survey sponsored by the ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that three-quarters of Americans nationwide and across party lines say it is personally important to them to find a cure or to prevent Alzheimer's disease, while a similar proportion of the national electorate say they look to Congress to make it "a national priority" to speed up the Food and Drug Administration's (FDA) review process in specific ways for therapies that slow, halt or reverse the disease.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
› Verified 8 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1245375203 | NPI | - | NPPES |
600014795 | Medicaid | LA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
251S00000X | Community/behavioral Health | (* (Not Available)) | Secondary |
261QR0405X | Clinic/center - Rehabilitation, Substance Use Disorder | (* (Not Available)) | Primary |
Provider Name | William V Garibaldi |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1538530076 PECOS PAC ID: 5991136889 Enrollment ID: I20200508001578 |
News Archive
Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.
Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).
Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability.
A new voter survey sponsored by the ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that three-quarters of Americans nationwide and across party lines say it is personally important to them to find a cure or to prevent Alzheimer's disease, while a similar proportion of the national electorate say they look to Congress to make it "a national priority" to speed up the Food and Drug Administration's (FDA) review process in specific ways for therapies that slow, halt or reverse the disease.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
› Verified 8 days ago
Provider Name | Gregory B Caudill |
---|---|
Provider Type | Practitioner - Psychiatry |
Provider Identifiers | NPI Number: 1477718013 PECOS PAC ID: 1951721281 Enrollment ID: I20201026001795 |
News Archive
Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.
Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).
Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability.
A new voter survey sponsored by the ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that three-quarters of Americans nationwide and across party lines say it is personally important to them to find a cure or to prevent Alzheimer's disease, while a similar proportion of the national electorate say they look to Congress to make it "a national priority" to speed up the Food and Drug Administration's (FDA) review process in specific ways for therapies that slow, halt or reverse the disease.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
› Verified 8 days ago
News Archive
Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.
Instrumentation Laboratory today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC).
Most existing treatments for pathological bone loss inhibit osteoclasts (bone-destroying cells) to limit bone degradation. However, by doing this, they also prevent bone formation since it is stimulated by the presence of these very same osteoclast cells. Researchers from the CNRS, Inserm and the Université de Montpellier and Université Jean Monnet - Saint-étienne have developed a new approach for preventing the destructive activity of osteoclasts without affecting their viability.
A new voter survey sponsored by the ACT-AD Coalition (Accelerate Cure/Treatments for Alzheimer's Disease) finds that three-quarters of Americans nationwide and across party lines say it is personally important to them to find a cure or to prevent Alzheimer's disease, while a similar proportion of the national electorate say they look to Congress to make it "a national priority" to speed up the Food and Drug Administration's (FDA) review process in specific ways for therapies that slow, halt or reverse the disease.
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
› Verified 8 days ago
Nursing Home Psychological Services Of Louisiana Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 109 Constellation Dr, Slidell, LA 70458 Phone: 256-825-4135 Fax: 256-825-4137 | |
Cindy C. D. Mcnitt, Lcsw, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 119 Aberdeen Dr, Slidell, LA 70461 Phone: 985-641-7400 Fax: 985-641-4717 | |
Day One Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1114 Joy Dr, Slidell, LA 70461 Phone: 985-218-5456 Fax: 985-326-7447 | |
Acadian Care Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 113 Christian Ln, Slidell, LA 70458 Phone: 985-781-7353 Fax: 985-781-7354 | |
The Equestrian Therapy Center Of Slidell Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32597 Cc Road, Slidell, LA 70460 Phone: 985-641-4934 Fax: 985-649-0982 | |
Coastline Counseling And Partners, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1114 Joy Dr, Slidell, LA 70461 Phone: 662-897-2467 | |
The Hope Center For Autism Needs Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1670 Old Spanish Trl, Slidell, LA 70458 Phone: 985-796-2525 Fax: 985-288-5360 |